Bone as an Endocrine Organ Relevant to Diabetes

Current Diabetes Reports

Volumn 14, Issue 12, 2014, Pages 1-8

  Booth, Sarah L ^a   Centi, Amanda J ^a   Gundberg, Caren ^b  

^a TUFTS UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; Diabetes; Insulin resistance; Osteocalcin

Indexed keywords

OSTEOCALCIN; BIOLOGICAL MARKER;

BONE DENSITY; BONE TURNOVER; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FRACTURE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; REVIEW; RISK ASSESSMENT; ANIMAL; BIOLOGICAL MODEL; BONE; ENDOCRINE SYSTEM; METABOLISM;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; DIABETES MELLITUS; ENDOCRINE SYSTEM; HUMANS; MODELS, BIOLOGICAL; OSTEOCALCIN;

EID: 84910124592     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0556-3     Document Type: Review

References (72)

1. Morrison LB, Bogan IK. Bone development in diabetic children: a roentgen study. Am J Med Sci. 1927;174:313–8.
2. Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann Intern Med. 2014;160:517–25.
3. Roy B. Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures. World J Diabetes. 2013;4:101–13.
4. Saito M, Kida Y, Kato S, Marumo K. Diabetes, collagen, and bone quality. Curr Osteoporos Rep. 2014;12:181–8.
5. Pan H, Wu N, Yang T, He W. Association between bone mineral density and type 1 diabetes mellitus: a meta-analysis of cross-sectional studies. Diabetes Metab Res Rev. 2014. in press.
6. Ogata N, Chikazu D, Kubota N, Terauchi Y, Tobe K, Azuma Y, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest. 2000;105:935–43.
7. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495–505.
8. Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin. 2009;25:1057–72.
9. Akin O, Erkaya S, Clinic MO, Education N. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density. Gynecol Endocrinol. 2003;17(1):19–29.
10. Schwartz AV, Schafer AL, Grey A, Vittinghoff E, Palermo L, Lui L-YL, et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res. 2013;28:1348–54. This multi-cohort study demonstrates that disruption of bone turnover (which in turn would decrease circulating total and uncarboxylated osteocalcin) has no effect on glucose metabolism.
11. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab. 2008;19:161–6.
12. Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013;9:43–55. This review is an in-depth review of the issues related to the theory of osteocalcin in human glucose metabolism.
13. Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012;481:314–20.
14. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456–69.
15. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci. 2008;105:5266–70.
16. Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2012;50:568–75.
17. Nakao M, Nishiuchi Y, Nakata M, Kimura T, Sakakibara S. Synthesis of human osteocalcins: gamma-carboxyglutamic acid at position 17 is essential for a calcium-dependent conformational transition. Pept Res. 1994;7:171–4.
18. Cairns JR, Price PA. Direct demonstration that the vitamin K-dependent bone Gla protein is incompletely gamma-carboxylated in humans. J Bone Miner Res. 1994;9:1989–97.
19. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142:296–308.
20. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142:309–19.
21. Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res. 2011;26:677–80.
22. Rosen CJ, Motyl KJ. No bones about it: insulin modulates skeletal remodeling. Cell. 2010;142:198–200.
23. Yoshikawa Y, Kode A, Xu L, Mosialou I, Silva BC, Ferron M, et al. Genetic evidence points to an osteocalcin-independent influence of osteoblasts on energy metabolism. J Bone Miner Res. 2011;26:2012–25.
24. Wei J, Ferron M, Clarke CJ, Hannun YA, Jiang H, Blaner WS, et al. Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Invest. 2014;124:1781–93.
25. Brennan-speranza TC, Henneicke H, Gasparini SJ, Blankenstein KI, Heinevetter U, Cogger VC, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest. 2012;122(11):4172–89.
26. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35.
27. Riddle RC, Frey JL, Tomlinson RE, Ferron M, Li Y, Digirolamo DJ, et al. Tsc2 is a molecular checkpoint controlling osteoblast development and glucose homeostasis. Mol Cell Biol. 2014;34:1850–62. This study proposes a model by which osteocalcin may influence glucose metabolism via the tumor suppressor Tsc2.
28. Rowe GC, Choi CS, Neff L, Horne WC, Shulman GI, Baron R. Increased energy expenditure and insulin sensitivity in the high bone mass DeltaFosB transgenic mice. Endocrinology. 2009;150:135–43.
29. Haffa A, Krueger D, Bruner J, Engelke J, Gundberg C, Akhter M, et al. Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J Bone Miner Res. 2000;15:872–8.
30. Shea MK, Gundberg CM, Meigs JB, Dallal GE, Saltzman E, Yoshida M, et al. Gamma-carboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr. 2009;90:1230–5.
31. Iki M, Tamaki J, Fujita Y, Kouda K, Yura A, Kadowaki E, et al. Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Osteoporos Int. 2012;23:761–70.
32. Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab. 2009;94:827–32.
33. Saleem U, Mosley Jr TH, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arteriosler Thromb Vasc Biol. 2010;30:1474–8.
34. Gravenstein KS, Napora JK, Short RG, Ramachandran R, Carlson OD, Metter EJ, et al. Cross-sectional evidence of a signaling pathway from bone homeostasis to glucose metabolism. J Clin Endocrinol Metab. 2011;96:E884–90.
35. Wieczorek-Baranowska A, Nowak A, Pilaczyńska-Szcześniak Ł. Osteocalcin and glucose metabolism in postmenopausal women subjected to aerobic training program for 8 weeks. Metabolism. 2012;61:542–5.
36. Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between obesity, metabolic risks and serum osteocalcin level in postmenopausal women. Gynecol Endocrinol. 2012;28:472–7.
37. Karlsson MK, Kindblom JM, Ohlsson C. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res. 2009;24(5):785–91.
38. Hwang YC, Jeong IK, Ahn KJ, Chung HY. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev. 2009;25:768–72.
39. Lucey AJ, Paschos GK, Thorsdottir I, Martínéz JA, Cashman KD, Kiely M. Young overweight and obese women with lower circulating osteocalcin concentrations exhibit higher insulin resistance and concentrations of C-reactive protein. Nutr Res. 2013;33:67–75.
40. Gower BA, Pollock NK, Casazza K, Clemens TL, Goree LL, Granger WM. Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and beta-cell function in overweight adults. J Clin Endocrinol Metab. 2013;98:E1173–80. This study demonstrates that multiple markers of bone turnover are related to glucose metabolism, which would suggest that associations between osteocalcin and glucose metabolism may be indicative of a larger role of bone in diabetes.
41. Bao Y, Ma X, Yang R, Wang F, Hao Y, Dou J, et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab. 2013;98:345–51.
42. Lu C, Ivaska KK, Alen M, Wang Q, Törmäkangas T, Xu L, et al. Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women. J Clin Endocrinol Metab. 2012;97:4106–14.
43. Polgreen LE, Jacobs DR, Nathan BM, Steinberger J, Moran A, Sinaiko AR. Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults. Obesity. 2012;20:2194–201.
44. Díaz-López A, Bulló M, Juanola-Falgarona M, Martínez-González MA, Estruch R, Covas M-I, et al. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case–control study. J Clin Endocrinol Metab. 2013;98:4524–31.
45. Paldánius PM, Ivaska KK, Hovi P, Andersson S, Eriksson JG, Väänänen K, et al. Total and carboxylated osteocalcin associate with insulin levels in young adults born with normal or very low birth weight. PLoS One. 2013;8:e63036.
46. Foresta C, Strapazzon G, De Toni L, Gianesello L, Calcagno A, Pilon C, et al. Evidence for osteocalcin production by adipose tissue and its role in human metabolism. J Clin Endocrinol Metab. 2010;95:3502–6.
47. Iglesias P, Arrieta F, Piñera M, Botella-Carretero JI, Balsa JA, Zamarrón I, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol. 2011;75:184–8.
48. Movahed A, Larijani B, Nabipour I, Kalantarhormozi M, Asadipooya K, Vahdat K, et al. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. J Bone Miner Metab. 2012;30:683–91.
49. Hwang Y-C, Jee J-H, Jeong I-K, Ahn KJ, Chung HY, Lee M-K. Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study. Diabetes Care. 2012;35:1919–24.
50. Truong JT, Fu X, Saltzman E, Al Rajabi A, Dallal GE, Gundberg CM, et al. Age group and sex do not influence responses of vitamin K biomarkers to changes in dietary vitamin K. J Nutr. 2012;142:936–41.
51. Yoshida M, Jacques PF, Meigs JB, Saltzman E, Shea MK, Gundberg C, et al. Effect of vitamin K supplementation on insulin resistance in older men and women. Diabetes Care. 2008;31:2092–6.
52. Kumar R, Binkley N, Vella A. Effect of phylloquinone supplementation on glucose homeostasis. Am J Clin Nutr. 2010;92:1528–32.
53. Choi HJ, Yu J, Choi H, An JH, Kim SW, Park KS, et al. Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: a placebo-controlled trial. Diabetes Care. 2011;34:e147.
54. Ibarrola-Jurado N, Salas-Salvado J, Martinez-Gonzalez MA, Bullo M. Dietary phylloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of cardiovascular disease. Am J Clin Nutr. 2012;96:1113–8.
55. Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol. 2012;8:81–91.
56. Vestergaard P. Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif Tissue Int. 2011;89:265–70.
57. Hong S-H, Koo J-W, Hwang JK, Hwang Y-C, Jeong I-K, Ahn KJ, et al. Changes in serum osteocalcin are not associated with changes in glucose or insulin for osteoporotic patients treated with bisphosphonate. J Bone Metab. 2013;20:37–41.
58. Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care. 1998;21:1589–95.
59. Kanaya AM. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1.
60. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004;47:1175–87.
61. Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther. 2003;25:919–30.
62. Anastasilakis AD, Efstathiadou Z, Plevraki E, Koukoulis GN, Slavakis A, Kita M, et al. Effect of exogenous intermittent recombinant human PTH 1–34 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity. Horm Metab Res. 2008;40:702–7.
63. Booth SL, Al Rajabi A. Determinants of vitamin K status in humans. Vitam Horm. 2008;78:1–22.
64. Hoang QQ, Sicheri F, Howard AJ, Yang DSC. Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature. 2003;425:977–80.
65. Arbour NC, Darwish HM, DeLuca HF. Transcriptional control of the osteocalcin gene by 1,25-dihydroxyvitamin D-2 and its 24-epimer in rat osteosarcoma cells. Biochim Biophys Acta. 1995;1263:147–53.
66. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984;1:1091–3.
67. Karsenty G. Bone endocrine regulation of energy metabolism and male reproduction. C R Biol. 2011;334:720–4.
68. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, et al. Endocrine regulation of male fertility by the skeleton. Cell. 2011;144:796–809. This study proposed that osteocalcin may have a role in fertility in male mice via the GPRC6A receptor.
69. Pi M, Wu Y, Quarles LD. GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J Bone Miner Res. 2011;26:1680–3.
70. Jacobsen SE, Nørskov-Lauritsen L, Thomsen ARB, Smajilovic S, Wellendorph P, Larsson NHP, et al. Delineation of the GPRC6A receptor signaling pathways using a mammalian cell line stably expressing the receptor. J Pharmacol Exp Ther. 2013;347:298–309. This study refutes the theory the osteocalcin may be associated with via the GPRC6A receptor.
71. Bolland MJ, Grey A, Horne AM, Reid IR. Testosterone levels following decreases in serum osteocalcin. Calcif Tissue Int. 2013;93:133–6.
72. Hannemann A, Breer S, Wallaschofski H, Nauck M, Baumeister SE, Barvencik F, et al. Osteocalcin is associated with testosterone in the general population and selected patients with bone disorders. Andrology. 2013;1:469–74.